Ligand Pharmaceuticals (LGND), GSK's (GSK) promacta approved - Report
Ligand Pharmaceuticals (NASDAQ: LGND), GSK's (NYSE: GSK) promacta approved for treatment of low blood platelet counts in HepC patients, Adam Feuerstein reports.
You May Also Be Interested In
- Tekmira Pharmaceuticals (TKMR) Stock Quietly Gains Steam on Ebola Outbreak
- GlaxoSmithKline plc (GSK), Genmab Report PROLONG Phase III Met Primary Endpoint
- Amarin (AMRN) Gains; Feuerstein Gets Postive
Create E-mail Alert Related CategoriesFDA, Trader Talk
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!